SCHEMBL2802763

SCHEMBL2802763

CS(=O)(=O)NC(=O)c1cnn2c(NCc3cccs3)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 3/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 4/20 0.38
SCD5 Q86SK9 2/20 0.37
EGLN1 Q9GZT9 2/20 0.37
HSD17B10 Q99714 1/20 0.36
ADAM17 P78536 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 1/20 0.36
SCD O00767 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802021 0.91 SPR (0.41) SPRALDH1A1LMNAKDM4EHPGD
SCHEMBL2799687 0.89 STAT6 (0.40) SPRALDH1A1LMNAKDM4EHPGD
SCHEMBL2801428 0.87 ALDH1A1 (0.39) SPRALDH1A1LMNAKDM4EHPGD
SCHEMBL2800647 0.86 NPC1 (0.39) SPRALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL2802186 0.85 VNN1 (0.43) ALDH1A1KDM4EHPGDSCD5HSD17B10
SCHEMBL2802391 0.85 SMN1; SMN2 (0.41) SPRALDH1A1LMNAKDM4EHPGD
SCHEMBL2800629 0.84 ALDH1A1 (0.40) SPRALDH1A1LMNAKDM4EHPGD
SCHEMBL2800864 0.84 CCR1 (0.42) SMN1; SMN2TP53
SCHEMBL2802693 0.84 TP53 (0.41) ALDH1A1LMNASMN1; SMN2TP53EGLN1
SCHEMBL2803183 0.84 SPR (0.38) SPRALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 SPR 2955/4885ALDH1A1 243/4885LMNA 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.